Chemotherapy Plus Radiation Therapy in Treating Patients With Primary Stage IVB Cervical Cancer

Last updated: July 18, 2017
Sponsor: Zhejiang Cancer Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cervical Cancer

Uterine Disorders

Treatment

N/A

Clinical Study ID

NCT03175848
ZJCH-2017-CRT
  • Ages 18-70
  • Female

Study Summary

This is a prospective, single arm, phase II trail to assess the effect of primary lesion radiotherapy in the treatment of stage IVB cervical cancer on the basis of systemic chemotherapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Biopsy-proven, invasive carcinoma of the cervix(squamous cell carcinoma,adenocarcinoma and adenosquamous carcinoma )

  2. KPS≥70

  3. FIGO stage IVB

  4. Age: 18-70

  5. ECOG (Eastern Cooperative Oncology Group) : 0-2

  6. The expected survival time is >6 months

  7. Chemotherapy and radiation have not been done before

  8. Normal hemodynamic indices before the recruitment (including white blood cellcount>4.0×109/L, neutrophil count>1.5×109/L, platelet count >100×109/L,hemoglobin≥90g/l, normal liver/kidney function)

  9. Able to understand this study and have signed informed consent.

Exclusion

Exclusion Criteria:

  1. Prior hysterectomy

  2. Metastases lesions are confirmed by pathology or image and are excluded as the secondprimary neoplasm

  3. Patients with brain metastasis or disseminated peritoneal metastasis

  4. Female in pregnancy or lactating

  5. Hypersensitivity of chemotherapeutic drugs (paclitaxel allergy)

  6. History of major psychiatric disorder

  7. Persons with physical or mental illness, without civil capacity or with limitedcapacity for civil conduct

  8. Patient with any other disease or condition is a contraindication forchemoradiotherapy

  9. The researchers consider the patient not appropriate to be enrolled

Study Design

Total Participants: 48
Study Start date:
May 05, 2017
Estimated Completion Date:
October 31, 2020

Study Description

Because of the apparent heterogeneity of stage IVB cervical cancer, at present there is no standard treatment.

This is a Phase II, single-center, single-arm, study of systemic chemotherapy plus lesion radiotherapy for primary stage IVB cervical cancer.

The primary objective of the study is to test the hypothesis that primary lesion radiotherapy leads to an improvement in progression-free survival time (PFS)for stage IVB cervical cancer.

For those patients under the clinical management of the recruiting investigator, the investigator will review the patient's medical records and determine if they would be a candidate for the study.

Upon confirmation of all eligibility criteria, the subject will be enrolled.Patients with beyond abdominal pelvic lymph node metastasis will first undergo 2 cycle systemic chemotherapy（TP/TC），then to evaluate the efficacy of chemotherapy, and for patients with chemotherapy effective（CR+PR+SD) followed by the primary lesion of regional radiotherapy (external irradiation plus brachytherapy)，concurrent chemotherapy （TP/TC） may be given according to the patients tolerant，finally, the patient will complete a total of 6 cycles of chemotherapy（TP/TC）.Distant metastasis of lymph node areas (e.g., supraclavicular, axillary, mediastinum, etc.) will be radiation after radiotherapy at the primary site according to patients tolerant.Patients with stage IVB cervical cancer with hematogenous metastasiswill first undergo 4 cycle systemic chemotherapy（TP/TC），then to evaluate the efficacy of chemotherapy, and for patients with chemotherapy effective（CR+PR+SD) followed by the primary lesion of regional radiotherapy (external irradiation plus brachytherapy)，concurrent chemotherapy （TP/TC） may be given according to the patients tolerant，finally, the patient will complete a total of 6 cycles of chemotherapy（TP/TC），after the primary radiotherapy, the treatment regimen for distant metastasis will be determined by MDT discuss or consultation.Quality of life will be evaluated before and after treatment. During therapy, the patient will have a weekly physical exam, vital signs collected, evaluation for pain, and review any side effects.

Subjects will undergo a post treatment follow-up period after completion of their radiation therapy. During this follow-up period, subjects will return for a medical and history review with a complete physical examination, review of any side effects, evaluation for outcomes and toxicity, and QoL.

Connect with a study center

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang 310022
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.